Safety and Immunogenicity of ExPEC10V in Japanese Adults

Phase 1, randomised, double-blind trial of ExPEC10V in invasive extraintestinal pathogenic Escherichia coli disease (IED) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Solicited Local Adverse Events at 14 days, Number of Participants with Solicited Systemic Adverse Events at 14 days and 2 more. Started Mar 2020; status: completed.